![R. Jacob Vogelstein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
R. Jacob Vogelstein
Direktor/Vorstandsmitglied bei
IAMBIC THERAPEUTICS, INC.
Profil
Dr. Rachel J.
Vogelstein is a Co-Founder & Managing Partner at Catalio Capital Management LP, a Chief Executive Officer at Cage Pharma, Inc., an Advisor at Mind-X Corp.
and a Director & Manager at Catalio Genesis Fund II LLC.
He is on the Board of Directors at Catalio Access Fund V LLC, Catalio Genesis Fund IV LLC, Catalio Special Opportunities Fund III LLC, Haystack Oncology, Inc., Iambic Therapeutics, Inc. and Catalio Genesis Fund II LLC.
He is primarily responsible for managing the firm and for making investments in private breakthrough biomedical technology companies.
He serves on the Investment Committee of Catalio’s flagship Nexus strategy and on the firmwide Management Committee.
Dr. Vogelstein was previously employed as a Partner by Camden Partners Private Equity and Global Domain Partners LLC, and an Advisor by Gigantum, Inc. He also served on the board at Aruene Corp.
and Metabolon, Inc.
He earned his BSc.
degree in Bio-Electrical Engineering from Brown University and his Ph.D.
degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.
Aktive Positionen von R. Jacob Vogelstein
| Unternehmen | Position | Beginn |
|---|---|---|
| IAMBIC THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.07.2021 |
Cage Pharma, Inc.
 Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical drugs | Vorstandsvorsitzender | 01.12.2017 |
Haystack Oncology, Inc.
 Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Operates as an oncology care and MRD testing center | Direktor/Vorstandsmitglied | - |
Catalio Capital Management LP (Investment Management)
 Catalio Capital Management LP (Investment Management) Investment ManagersFinance Catalio-IM aims to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management and execution. The firm’s public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy that invests in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data. The strategy’s investment style is a “best idea” orientation focused on identifying mis-priced risk in clinical, regulatory, intellectual property, manufacturing, commercial, and management. | Vorstandsvorsitzender | 01.01.2020 |
Catalio Genesis Fund IV LLC
 Catalio Genesis Fund IV LLC Investment ManagersFinance Functions as a venture capital fund | Direktor/Vorstandsmitglied | - |
Catalio Genesis Fund II LLC
 Catalio Genesis Fund II LLC Investment ManagersFinance Functions as a venture capital fund | Direktor/Vorstandsmitglied | - |
Catalio Special Opportunities Fund Iii LLC
 Catalio Special Opportunities Fund Iii LLC Investment ManagersFinance Functions as a venture capital fund | Direktor/Vorstandsmitglied | - |
Catalio Access Fund V LLC
 Catalio Access Fund V LLC Investment ManagersFinance Functions as a venture capital fund | Direktor/Vorstandsmitglied | - |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Gründer | 01.06.2020 |
| ░░░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Ehemalige bekannte Positionen von R. Jacob Vogelstein
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von R. Jacob Vogelstein
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
62
Beziehungen ersten Grades
17
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 17 |
|---|---|
Metabolon, Inc.
 Metabolon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides metabolomics analysis and bioinformatics software solutions | Commercial Services |
Global Domain Partners LLC
 Global Domain Partners LLC Investment Banks/BrokersFinance Provides security and trading services | Finance |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Camden Partners Private Equity
 Camden Partners Private Equity Investment ManagersFinance Camden Partners invests in lower middle market companies located in the United States with an enterprise value ranging from USD 10 to 150 million and revenues of USD 10 to 50 million. The firm target companies operating in the fields of technology & software, tech & business services and education. It provides financing for buyout and growth stage transactions with an investment size ranging from USD 5 to 15 million. | Finance |
Aruene Corp.
 Aruene Corp. Medical SpecialtiesHealth Technology Develops portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for treatment of migraine | Health Technology |
Cage Pharma, Inc.
Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical drugs | Health Technology |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mind-X Corp.
 Mind-X Corp. Packaged SoftwareTechnology Services Develops software applications | Technology Services |
Gigantum, Inc.
 Gigantum, Inc. Packaged SoftwareTechnology Services Develops open-source platform | Technology Services |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Finance |
Entos, Inc.
 Entos, Inc. BiotechnologyHealth Technology Operates as a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform | Health Technology |
Catalio Access Fund V LLC
Catalio Access Fund V LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Genesis Fund II LLC
Catalio Genesis Fund II LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Genesis Fund IV LLC
Catalio Genesis Fund IV LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Special Opportunities Fund Iii LLC
Catalio Special Opportunities Fund Iii LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Operates as an oncology care and MRD testing center | Health Services |
Catalio Capital Management LP (Investment Management)
Catalio Capital Management LP (Investment Management) Investment ManagersFinance Catalio-IM aims to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management and execution. The firm’s public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy that invests in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data. The strategy’s investment style is a “best idea” orientation focused on identifying mis-priced risk in clinical, regulatory, intellectual property, manufacturing, commercial, and management. | Finance |
